Yijun Zeng
YOU?
Author Swipe
View article: Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States
Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States Open
Background In 2023, experts from the European and American regions proposed the concepts of steatotic liver disease (SLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD was proposed as a replacement for nonalco…
View article: Synbiotic Effects of Lacticaseibacillus paracasei K56 and Prebiotics on the Intestinal Microecology of Children with Obesity
Synbiotic Effects of Lacticaseibacillus paracasei K56 and Prebiotics on the Intestinal Microecology of Children with Obesity Open
Lacticaseibacillus paracasei K56 (L. paracasei K56) is a probiotic with weight-loss effects. However, symbiosis research on the combined effects of Lacticaseibacillus paracasei K56 and prebiotics is lacking. Therefore, the aim of this stud…
View article: Visualization obesity risk prediction system based on machine learning
Visualization obesity risk prediction system based on machine learning Open
Obesity is closely associated with various chronic diseases.Therefore, accurate, reliable and cost-effective methods for preventing its occurrence and progression are required. In this study, we developed a visualized obesity risk predicti…
View article: Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals
Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals Open
The difference in the survival of obese patients and normal-weight/lean patients with diabetic MAFLD remains unclear. Therefore, we aimed to describe the long-term survival of individuals with diabetic MAFLD and overweight/obesity (OT2M), …
View article: Clinical characteristics and mortality outcomes associated with subtypes of steatotic liver disease in the United States
Clinical characteristics and mortality outcomes associated with subtypes of steatotic liver disease in the United States Open
Background In 2023, experts from the European and American regions proposed the concepts of steatotic liver disease (SLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD was proposed as a replacement for NAFLD. …
View article: Lung imaging characteristics in a patient infected with <i>Elizabethkingia miricola</i> following cerebral hemorrhage surgery: A case report
Lung imaging characteristics in a patient infected with <i>Elizabethkingia miricola</i> following cerebral hemorrhage surgery: A case report Open
BACKGROUND Elizabethkingia miricola is a non-fermenting gram-negative bacterium, which was first isolated from the condensate of the Russian peace space station in 2003. Most studies on this bacterium have been carried out in the laborator…
View article: Developing a hypertension visualization risk prediction system utilizing machine learning and health check-up data
Developing a hypertension visualization risk prediction system utilizing machine learning and health check-up data Open
View article: Urinary circular RNA panels to help diagnose hepatitisB virus–related hepatocellular carcinoma: a multi-center, large scale and case-control study
Urinary circular RNA panels to help diagnose hepatitisB virus–related hepatocellular carcinoma: a multi-center, large scale and case-control study Open
Background: Over 60% of patients with hepatocellular carcinoma (HCC) do not receive curative therapitics due to late clinical manifestations and diagnosis. The 5-year survival rate for advanced HCC is around 2%. Curative therapies for earl…
View article: Supplementary Figure S5 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S5 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Metformin attenuates ABT-263-induced MCL-1, XIAP and SURVIVIN through neither transcriptional nor posttranslational regulation.
View article: Supplementary Figure S1 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S1 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
The synergistic effect between metformin and ABT-263 is independent of the cell cycle changes and metformin sensitizes ABT-263 not via changing the levels of BCL-2, BCL-XL, cIAP1 and cIAP2.
View article: Supplementary Figure S3 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S3 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Silencing or overexpressing the indicated genes in the presence of ABT-263 alone or the combination of metformin and ABT-263.
View article: Supplementary Figure S2 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S2 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Combination of metformin with ABT-263 had no significant growth inhibition effect on HEK-293 cells.
View article: Supplementary Figure S3 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S3 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Silencing or overexpressing the indicated genes in the presence of ABT-263 alone or the combination of metformin and ABT-263.
View article: Supplementary Figure S8 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S8 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Cotreatment with metformin and ABT-263 more remarkably elevates SASP components and p-ATM in p53-WT cancer cells compared to p53-defective cancer cells and the cotreatment increases p53 in p53-WT cancer cells.
View article: Supplementary Figure S8 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S8 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Cotreatment with metformin and ABT-263 more remarkably elevates SASP components and p-ATM in p53-WT cancer cells compared to p53-defective cancer cells and the cotreatment increases p53 in p53-WT cancer cells.
View article: Data from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Data from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
p53 deficiency, a frequent event in multiple kinds of malignancies, decreases the sensitivity of diverse targeted chemotherapeutics including the BCL-XL/BCL-2 inhibitor ABT-263. Loss of p53 function can activate mTOR complex 1 (mTORC1), wh…
View article: Data from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Data from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
p53 deficiency, a frequent event in multiple kinds of malignancies, decreases the sensitivity of diverse targeted chemotherapeutics including the BCL-XL/BCL-2 inhibitor ABT-263. Loss of p53 function can activate mTOR complex 1 (mTORC1), wh…
View article: Supplementary Figure S4 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S4 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Input analysis of corresponding Co-IP.
View article: Supplementary Figure S2 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S2 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Combination of metformin with ABT-263 had no significant growth inhibition effect on HEK-293 cells.
View article: Supplementary Figure S4 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S4 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Input analysis of corresponding Co-IP.
View article: Supplementary Figure S6 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S6 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
The influence of the cotreatment with metformin and ABT-263 on different translation-relevant kinase signaling pathways.
View article: Supplementary Figure S1 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S1 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
The synergistic effect between metformin and ABT-263 is independent of the cell cycle changes and metformin sensitizes ABT-263 not via changing the levels of BCL-2, BCL-XL, cIAP1 and cIAP2.
View article: Supplementary Figure S7 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S7 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Metformin and ABT-263 synergistically inhibit the growth of p53-defective (but not p53-WT) cancer cells and the metformin/ABT-263 combination more effectively elicits apoptosis in p53-defective xenograft tumors compared to p53-WT xenograft…
View article: Supplementary Figure S7 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S7 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Metformin and ABT-263 synergistically inhibit the growth of p53-defective (but not p53-WT) cancer cells and the metformin/ABT-263 combination more effectively elicits apoptosis in p53-defective xenograft tumors compared to p53-WT xenograft…
View article: Supplementary Figure S6 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S6 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
The influence of the cotreatment with metformin and ABT-263 on different translation-relevant kinase signaling pathways.
View article: Supplementary Figure S5 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Supplementary Figure S5 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells Open
Metformin attenuates ABT-263-induced MCL-1, XIAP and SURVIVIN through neither transcriptional nor posttranslational regulation.
View article: Protective effects of brain and muscle ARNT-like gene 1 on oxidized low-density lipoprotein-induced human brain microvascular endothelial cell injury by alleviating ferroptosis
Protective effects of brain and muscle ARNT-like gene 1 on oxidized low-density lipoprotein-induced human brain microvascular endothelial cell injury by alleviating ferroptosis Open
Ferroptosis plays an important role in atherosclerotic cerebrovascular diseases. The brain and muscle ARNT-like gene 1 (BMAL1) is an important mediator in the progression of cerebrovascular diseases. However, whether BMAL1 regulates ferrop…
View article: A Review of Foreign Language Enjoyment and Engagement
A Review of Foreign Language Enjoyment and Engagement Open
The introduction of positive psychology into foreign/second language learning has led to a multitude of novel theoretical and empirical studies. Foreign language enjoyment (FLE) is regarded as a response to the widely examined concept of c…
View article: Urinary miR-93-5p as A Promising Biomarker for Early HBV-Related Hepatocellular Carcinoma
Urinary miR-93-5p as A Promising Biomarker for Early HBV-Related Hepatocellular Carcinoma Open
Background: The mortality rate of early HBV-related hepatocellular carcinoma (HCC) is increasing annually due to sensitive and readily available diagnostic tools are lacking. This study aims to find such diagnostic biomarkers. Methods: MiR…
View article: The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma
The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma Open
Paclitaxel is highly effective at killing many malignant tumors; however, the development of drug resistance is common in clinical applications. The issue of overcoming paclitaxel resistance is a difficult challenge at present. In this stu…